Is the purchasing channel for tucatinib/tucatinib reliable?

Tucatinib is a highly selective small molecule inhibitor targeting HER2 tyrosine kinase. Its main indication is the treatment of patients with HER2-positive advanced or metastatic breast cancer, especially those who have received trastuzumab, pertuzumab and taxane chemotherapy drugs. It is worth noting that tucatinib can be used in combination with trastuzumab and capecitabine to form a triple regimen, which provides new treatment possibilities for patients who have failed multiple lines of treatment. It especially shows significant advantages in patients with brain metastases, which is a highlight that distinguishes it from traditional anti-HER2 drugs.

In addition, tucatinib has also been explored in some clinical studies for the treatment of other HER2-expressing solid tumors, including HER2-positive colorectal cancer. However, these indications are still in the trial or early registration stage and have not yet been widely approved. For breast cancer patients, tucatinib has a highly specific target and relatively low side effects. It is an important supplement after trastuzumab and small molecule lapatinib.

At present, since tucatinib has not yet been officially launched in China, some patients may consider obtaining the drug through overseas channels. However, there are greater risks in such unofficial channels, such as unknown sources of drugs, irregular storage and transportation conditions, and counterfeit drugs, which may pose a threat to patient safety. In addition, it is difficult for drugs without regulatory approval to obtain comprehensive guidance and monitoring from doctors in the domestic medical system, which may result in poor efficacy or poor control of side effects.

Therefore, if a patient really needs to use tucatinib, it is recommended to obtain it through formal platforms and other mechanisms and conduct treatment under the guidance of professional oncologists. Standardized channels can not only ensure the authenticity and effectiveness of drugs, but also provide necessary drug consultation services to avoid adverse consequences caused by blind medication.

Reference materials:https://www.tukysa.com/